Compare UPWK & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPWK | TYRA |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2018 | 2021 |
| Metric | UPWK | TYRA |
|---|---|---|
| Price | $10.93 | $39.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | $22.73 | ★ $46.38 |
| AVG Volume (30 Days) | ★ 2.9M | 975.1K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $787,784,000.00 | N/A |
| Revenue This Year | $9.10 | N/A |
| Revenue Next Year | $13.60 | N/A |
| P/E Ratio | $13.02 | ★ N/A |
| Revenue Growth | ★ 2.40 | N/A |
| 52 Week Low | $10.52 | $6.42 |
| 52 Week High | $22.84 | $40.65 |
| Indicator | UPWK | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 34.86 | 63.74 |
| Support Level | N/A | $20.86 |
| Resistance Level | $13.97 | N/A |
| Average True Range (ATR) | 0.48 | 2.34 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 19.81 | 84.34 |
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes and connects businesses with AI-enabled talent across every on-demand work type, including freelance, agency, fractional, and payrolled. The business generates revenue from Talent and Clients across the USA, India, Pakistan, the Philippines and the rest of the world. Maximum revenue of the company is derived from Talent segment.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.